Moderna advancing early stage mRNA prospects to show depth beyond COVID-19 shot

Moderna, sitting on a powder keg of cash after launching a COVID-19 vaccine that's being distributed around the world, is not going to be resting on its laurels anytime soon.

New interim phase 1 data for the biotech's respiratory syncytial virus, or RSV, vaccine candidate called mRNA-1345 showed the treatment was well tolerated in younger adults and increased neutralizing antibodies in patients with the virus. The candidate is based on the same mRNA technology that brought the COVID-19 vaccine to the world.